Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
UNSEALED SOURCE THERAPY OF PAINFUL BONE METASTASES - AN UPDATE
Autore:
MCEWAN AJB;
Indirizzi:
CROSS CANC INST,DEPT ONCOL IMAGING,11560 UNIV AVE EDMONTON AB T6G 1Z2CANADA UNIV ALBERTA,DEPT RADIOL & DIAGNOST IMAGING EDMONTON AB T6G 2M7 CANADA UNIV ALBERTA HOSP EDMONTON AB CANADA
Titolo Testata:
Seminars in nuclear medicine
fascicolo: 2, volume: 27, anno: 1997,
pagine: 165 - 182
SICI:
0001-2998(1997)27:2<165:USTOPB>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
SR-89 RADIONUCLIDE THERAPY; SM-153 ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONATE; RE-186 HYDROXYETHYLIDENE DIPHOSPHONATE; REFRACTORY PROSTATE CARCINOMA; STRONTIUM PLASMA-CLEARANCE; DOUBLE-BLIND CROSSOVER; OSSEOUS METASTASES; SKELETAL METASTASES; EXTERNAL-BEAM; PALLIATIVE THERAPY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
126
Recensione:
Indirizzi per estratti:
Citazione:
A.J.B. Mcewan, "UNSEALED SOURCE THERAPY OF PAINFUL BONE METASTASES - AN UPDATE", Seminars in nuclear medicine, 27(2), 1997, pp. 165-182

Abstract

Pain in patients with cancer metastatic to bone is a significant cause of morbidity and of referrals from general practice and specialist physicians. Management typically utilizes radiation therapy and the graduated use of opiate analgesics. Bone-seeking radiopharmaceuticals have provided a new option to these management strategies, which is effective and cost effective, Strontium 89 is now in routine clinical use, while rhenium 186 hydroxyethylidene diphosphonate (HEDP) and samarium 153 ethylenediaminetetramethylene phosphonate (EDTMP) are in Phase IIItrials and tin 117m (4+) diethylene triaminepentacetic acid (DTPA) isin Phase I trials. Evidence taken primarily from the Strontium 89 trial, shows unsealed source therapy with these bone-seeking radiopharmaceuticals to be effective in palliating pain, improving quality of life, reducing the rate at which new painful sites develop, reducing requirements for additional radiation therapy, and reducing lifetime management costs. Indications and contraindications to therapy have now beendefined, and retreatment is an option with all radiopharmaceuticals. Copyright (C) 1997 by W.B. Saunders Company.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:37:04